Condition
Serology
Total Trials
4
Recruiting
1
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 4 (1)
Trial Status
Completed2
Recruiting1
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06917560Active Not Recruiting
Serological Autoantibodies in Early Kidney Cancer Diagnosis and Prognosis: A Multicenter Study
NCT05266898Phase 4Recruiting
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
NCT04620798Not ApplicableCompleted
Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students
NCT04356586Completed
Immune Response to Covid-19 in 300 Health Care Workers With Mild Symptoms
Showing all 4 trials